Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Due to unique advantages that allow high-dimensional tissue profiling, we postulated imaging mass cytometry (IMC) may shed novel insights on the molecular makeup of proliferative lupus nephritis (LN). This study interrogates the spatial expression profiles of 50 target proteins in LN and control kidneys. Proliferative LN glomeruli are marked by podocyte loss with immune infiltration dominated by CD45RO+, HLA-DR+ memory CD4 and CD8 T-cells, and CD163+ macrophages, with similar changes in tubulointerstitial regions. Macrophages are the predominant HLA-DR expressing antigen presenting cells with little expression elsewhere, while macrophages and T-cells predominate cellular crescents. End-stage sclerotic glomeruli are encircled by an acellular fibro-epithelial Bowman's space surrounded by immune infiltrates, all enmeshed in fibronectin. Proliferative LN also shows signs indicative of epithelial to mesenchymal plasticity of tubular cells and parietal epithelial cells. IMC enabled proteomics is a powerful tool to delineate the spatial architecture of LN at the protein level.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2023.109713 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ROS-induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus.
Arthritis Rheumatol
September 2025
Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, Italy.
Objective: Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear. This study investigated the potential role of oxidative stress-induced alterations in fibrinogen structure and function in the pathogenesis of atherothrombosis in SLE.
View Article and Find Full Text PDFIsolated Antiphospholipid Syndrome Nephropathy (aPL Nephropathy)-A Rare Cause of a Rapid Decline in Kidney Function in a Patient With Systemic Lupus Erhythematosus.
Nephrology (Carlton)
August 2025
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Lupus nephritis (LN) is one of the most common renal manifestations of systemic lupus erythematosus (SLE). However, conditions other than LN can result in a rapid decline in kidney function. We present a clinical case of a young patient with SLE who developed arterial hypertension, arthralgia and morning stiffness in knee and hand joints, an increase in serum creatinine levels from 194 to 532 mol/L, proteinuria of 1.
View Article and Find Full Text PDFEfficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study.
RMD Open
August 2025
Novartis Pharma AG, Basel, Switzerland
Background: Iscalimab (CFZ533) is a novel, anti-CD40 monoclonal antibody. This study evaluated the efficacy, pharmacokinetics and safety of iscalimab versus placebo as add-on to standard-of-care (SoC) therapy in patients with biopsy-proven active proliferative lupus nephritis (LN).
Methods: This was a phase II, randomised, double-blind, placebo-controlled, multicentre study including patients with a diagnosis of systemic lupus erythematosus with active LN.
Serum NF-κB-Regulated Biomarkers of Proliferative Lupus Nephritis.
Glomerular Dis
June 2025
Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Introduction: Lupus nephritis (LN) is kidney inflammation that commonly occurs from systemic lupus erythematosus. NF-κB activity is increased in LN patients, leading to elevated circulating concentrations of immune modulators that contribute to LN pathophysiology. This study sought to investigate this phenomenon with the aim of discovering novel serum biomarkers for LN.
View Article and Find Full Text PDFGlobal clinical trials on stem cell therapy for autoimmune diseases: trends and future directions.
Front Immunol
August 2025
School of Basic Medical Sciences, Zhejiang University of Chinese Medicine, Hangzhou, China.
Background: Autoimmune diseases, such as Crohn's disease (CD) and systemic lupus erythematosus (SLE), lead to progressive multi-organ damage due to immune dysregulation and chronic inflammation. Current therapies lack efficacy and safety, often failing to sustain remission. Stem cell therapy has emerged as a promising approach for immune modulation and tissue repair.
View Article and Find Full Text PDF